TETRAVECTA
LIVE

Serial Number

98432248

Owner

Oxford BioMedica Plc

Attorney

Rebeccah Gan

Filing Date

Mar 4, 2024

Add to watchlist:

No watchlists yet
View on USPTO

TETRAVECTA Trademark

Serial Number: 98432248

TETRAVECTA is a trademark filed by Oxford BioMedica Plc on March 4, 2024. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

Oxford BioMedica Plc

Windrush Court, Transport Way
Oxford OX46LT , GB

Entity Type: 99

Trademark Details

Filing Date

March 4, 2024

Registration Date

Not Registered

Goods & Services

Custom manufacture of products relating to biotechnology, namely, custom manufacture of biopharmaceuticals for use in cell and gene therapies; custom manufacture of gene and cell-based therapy products, namely, genetically engineered cells and tissues for cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vectors, and non-vector preparations in the nature of biopharmaceuticals used in cell and gene therapies, and biopharmaceutical preparations; biotechnology contract manufacturing services, namely, contract manufacturing in the field of pharmaceuticals and biopharmaceuticals for cell and gene therapy using biological organisms in the manufacturing process; contract manufacturing services of gene and cell-based therapy products, namely, biopharmaceuticals for cell and gene therapies, genetically engineered viral vectors, genetically engineered retroviral vectors, genetically engineered lentiviral vectors, genetically engineered adeno-associated viral vectors, genetically engineered adenoviral vectors, and non-vector preparations in the nature of biopharmaceuticals for cell and gene therapies and biopharmaceutical products, namely, biopharmaceuticals for cell and gene therapies; contract manufacturing services of technology for biopharmaceutical products and gene and cell-based products, namely, custom manufacture of biopharmaceuticals for cell and gene therapies; contract manufacturing services of technology for viral vectors, retroviral vectors, lentiviral vectors, adeno-associated viral vectors, adenoviral vectors, and non-vector preparations, namely, custom manufacture of pharmaceuticals and biopharmaceuticals for cell and gene therapies

Research and laboratory analytic and diagnostic services, namely, scientific research, biochemical research, research laboratory analysis services in the field of gene therapy and biochemistry; product development consultancy in the field of nanotechnology, gene therapy and vector-based delivery systems; product, viral vector product and analytic assay product development for others; laboratory services, namely, scientific laboratory services and biological research laboratory services; research and development services, namely, gene therapy research; genetic engineering laboratories, namely, scientific research in the field of genetic engineering provided in genetic engineering laboratories and biochemistry laboratories providing research and development in the field of biochemistry; scientific and technological services and research, namely, scientific research, analysis, testing in the fields of gene therapy and biochemistry; industrial analysis services, namely, providing testing analysis services with respect to gene-therapy based product manufacturing for industrial purposes; provision of information relating to scientific research; provision of scientific information in the fields of gene therapy and biochemistry; product research and scientific analysis of cell and gene therapies relating to drug discovery and product development for others; scientific advisory services relating to biochemistry; scientific consultancy services relating to biochemistry; scientific research and development; scientific research in the field of biotechnology and pharmaceuticals

Filing History

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Jul 23, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Jul 23, 2026 XELR
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Apr 25, 2026 GNS2
INQUIRY TO SUSPENSION E-MAILED
Apr 25, 2026 GNSI
SUSPENSION INQUIRY WRITTEN
Apr 25, 2026 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 25, 2026 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 20, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 20, 2025 GNSL
SUSPENSION LETTER WRITTEN
Oct 20, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 17, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 17, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Oct 17, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 9, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 9, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 9, 2025 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 22, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 21, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 21, 2025 GNSL
SUSPENSION LETTER WRITTEN
Jan 21, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 24, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 23, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 23, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 25, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 25, 2024 GNRT
NON-FINAL ACTION WRITTEN
Sep 25, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 18, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 15, 2024 NWOS
NEW APPLICATION ENTERED
Mar 4, 2024 NWAP